VolitionRx Limited (VNRX) - 10-Q Summary
Business Context and Reporting Period
Company: VolitionRx Limited (VNRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: VolitionRx is a multi-national epigenetics company developing blood tests for early detection of cancer and sepsis (NETosis). Key products include the Nu.Q® Vet Cancer Test (veterinary) and Nu.Q® NETs (human). The company is transitioning from R&D to commercialization, relying on licensing and distribution partnerships (e.g., Heska, IDEXX, Werfen, Hologic).
Listing Status: NYSE American. The company is currently under a compliance plan to regain listing standards regarding stockholders' equity, with a deadline of August 6, 2027.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (USD) |
|---|---|
| Total Revenues | $1,383,733 |
| Net Loss | $(14,018,820) |
| Net Loss Attributable to Common Stockholders | $(14,450,921) |
| Operating Loss | $(9,527,671) |
| Cash and Cash Equivalents (End of Period) | $2,790,994 |
| Net Cash Used in Operating Activities | $(10,439,781) |
| Net Cash Provided by Financing Activities | $12,595,212 |
| Total Current Liabilities | $13,492,636 |
| Stockholders' Deficit | $(33,539,360) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 112% year-over-year (from $0.65M to $1.38M), driven by a 252% increase in product revenue ($1.32M vs $0.38M) due to Nu.Q® Vet sales and deferred revenue recognition adjustments. Services revenue declined 79%.
- Expense Reduction: Total operating expenses decreased 13% to $10.9M (from $12.5M), primarily due to reduced personnel expenses and stock-based compensation across R&D, G&A, and Sales/Marketing.
- Increased Net Loss: Despite lower operating expenses, the Net Loss increased 19% to $14.0M. This was driven by significant non-cash "Other Expenses" totaling $4.5M, including a $1.58M loss on extinguishment of debt, $1.28M loss on change in fair value of derivative liabilities, and $0.86M amortization of debt discount.
- Debt and Equity: The company raised approximately $12.6M in financing activities, including a June 2026 public offering ($4.1M net) and ATM sales ($6.6M). Concurrently, the company issued shares to repay convertible notes (Lind Notes), resulting in significant debt extinguishment losses.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year. The company relies on future financing, licensing deals, or grant funding to sustain operations.
- Unusual Items:
- Debt Extinguishment: A $1.58M loss was recognized from issuing shares to repay Lind Notes.
- Derivative Liability: A $1.28M loss on the change in fair value of derivative liabilities embedded in convertible notes.
- Deemed Dividend: A $460,100 non-cash deemed dividend was recorded due to a down-round provision adjustment on warrants following the June 2026 equity offering.
- Risks:
- Failure to raise additional capital could force cessation of operations.
- Non-compliance with NYSE American listing standards (stockholders' equity below $6.0M) remains a risk until August 2027.
- Material weaknesses in internal controls over financial reporting persist.
- Outlook: Management plans to prioritize clinical validation studies and licensing deals. Reimbursement submissions for the Nu.Q® NETs test in Europe and the Nu.Q® Lung Cancer test in France are underway.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.8M cash balance against the $10.4M operating cash burn rate and upcoming debt obligations.
- Debt Covenants: Review the terms of the Lind Notes (2025 and 2026), specifically the market capitalization covenants and the recent waiver of acceleration rights, to assess default risk.
- Listing Compliance: Monitor progress on the plan to regain NYSE American compliance (targeting $6.0M stockholders' equity) by August 2027.
- Revenue Quality: Assess the sustainability of the 112% revenue growth, noting the impact of deferred revenue recognition adjustments versus organic sales growth.
- Internal Controls: Review the status of remediation efforts for the identified material weaknesses in internal financial reporting controls.